Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioMind Inc.

www.cardiomind.com

Latest From CardioMind Inc.

Next-Generation Coronary Stent Start-Ups: Making a Difference in a Mature Market

Which kinds of innovations make for incremental enhancements in the hands of large companies and which are meaningful enough to sustain a venture-backed start-up company? In a mature market for coronary stents dominated by large companies, start-ups developing new stents need to find the answers. Areas of innovation fall into four basic categories: improving stent safety and biocompatibility, avoiding the need for dual antiplatelet therapy, enhancing deliverability, and introducing specialty stents for complex vessels. Three companies profiled here have a plan for taking sufficient market share, reducing risk, and rewarding investors.
Medical Device Platform Technologies

Start-Up News

Noteworthy news from medtech start-ups. This month we profile Epicardial Technologies Inc., which is developing technology for percutaneous epicardial ablation of heart arrhythmias, Svelte Medical's technology for enhancing stent deliverability, Bioring's biodegradable annuloplasty ring and Advanced BioSensor's second-generation glucose monitoring device.
Medical Device

The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs

Growth by innovation is almost considered a birthright in interventional cardiology, and based on presentations at this year's Transcatheter Cardiovascular Therapeutics meeting, held this September in San Francisco, it seems clear that innovation still reigns supreme in this specialty. However, as in other medical device markets, ongoing economic and regulatory pressures are taking their toll, particularly in the drug-eluting stent market, as the field adjusts to a new era of cost control and economic uncertainty.
Medical Device

Medical Device Investing: Financing in an Economic Crisis

At FDC-Windhover's October IN3 East conference, we asked a distinguished panel of experienced venture capitalists to share their insights on the downturn in medtech venture investing. We invited our panelists to weigh in on the role of the current crisis in the second and third quarter slowdown in device investing and what it would mean going forward for a sector that had been so frothy just a short time earlier.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CardioMind Inc.
  • Senior Management
  • Julian Nikolchev, Pres. & CEO
  • Contact Info
  • CardioMind Inc.
    Phone: (408) 329-5200
    257 Humboldt Ct.
    Sunnyvale, CA 94089
    USA
UsernamePublicRestriction

Register